Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, MA / ACCESSWIRE / March 16, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement with the Ministry of Health, Labour and Welfare of Japan (MHLW) to supply Japan with an additional 70 million doses of Moderna's COVID-19 booster vaccine or an updated booster vaccine candidate, if authorized, for anticipated delivery in the second half of 2022. This agreement is subject to the Ministry securing a budget for the additional supply.

Moderna and the Japanese Government Reach an Agreement to Supply Japan with Additional 70 Million Doses of Moderna's COVID-19 Booster Vaccine

Moderna's (MRNA) Management Presents at Barclays Global Healthcare Conference (Transcript)

AstraZeneca

LumiraDx Ltd

Valneva SE

Could health care stocks be the top picks in the stock market this week?

Good Stocks To Buy Right Now? 4 Health Care Stocks For Your List

Moderna (MRNA) stock is in the news today as the company's president counters recent statements made by Pfizer's (PFE) CEO. The post Moderna News: What Has MRNA Stock Moving This Week?

Moderna News: What Has MRNA Stock Moving This Week?

Moderna (MRNA) starts dosing in an mRNA-based HIV vaccine study.

Moderna (MRNA) Early-Stage HIV Vaccine Study Begins, Stock Up

Moderna (MRNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Moderna (MRNA) Stock Jumps 8.6%: Will It Continue to Soar?

Investors are excited about the potential of the company's new HIV vaccine.

Why Moderna Stock Surged Today

Young, healthy people may choose not to get boosted if they're not concerned about infection or mild disease, Moderna President Stephen Hoge said.

Moderna president says 4th COVID-19 shot is probably only necessary for older and immunocompromised people

BioNTech SE

Johnson & Johnson

Novavax

Pfizer

Shares of Moderna, BioNTech, Pfizer, Johnson & Johnson and Novavax rose on Monday as China battles its worst Covid outbreak in two years.

Vaccine maker stocks rise as China battles worst Covid outbreak since 2020

PepsiCo

The Nasdaq Composite continued to lose ground, but these stocks held up.

2 Nasdaq Stocks Bucking Monday's Market Drop

Moderna Inc (NASDAQ: MRNA) has dosed the first participant in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine (mRNA-1574). The open-label, multicenter, randomized Phase 1 trial (HVTN 302) is designed to evaluate the safety and.

Moderna Moves Forward With Second HIV Vaccine Trial

Shares of Covid-19 vaccine makers jump on news of climbing Covid-19 cases in China and growing talk of a fourth booster round in the U.S.

Moderna and BioNTech Stocks Rally on Booster Chatter and a China Covid Surge

Shares of Moderna Inc. MRNA, +18.23% soared 19.2% in trading on Monday after the company announced that it began dosing participants in a Phase 1 clinical trial of its experimental HIV vaccine. The trial is an open-label, randomized study evaluating the investigational mRNA vaccine in 100 adults between the ages of 18 and 55 years who are HIV negative.

Moderna begins testing experimental HIV vaccine in an early-stage clinical trial

CAMBRIDGE, MA / ACCESSWIRE / March 14, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant has been dosed in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine (mRNA-1574). "Developing a vaccine regimen that induces sustained protective levels of HIV neutralizing antibodies in humans has been difficult to achieve.

Moderna Announces First Participant Dosed in Phase 1 Study of its HIV Trimer mRNA Vaccine

The discount in MRNA stock will not last forever given Moderna's steady cash flow growth potential from its Covid-19 vaccine. The post The Freefall in Moderna Stock Will End Eventually appeared first on InvestorPlace.

The Freefall in Moderna Stock Will End Eventually

Fulgent Genetics

Below stocks have been added to my watchlist.

2 Top Biotech Stocks With Huge Potential

Moderna (MRNA) administers the first dose in the phase II study of its Omicron-specific bivalent booster candidate (mRNA-1273.214). It expects to enrol 375 subjects for the same in the United States.

Moderna (MRNA) Starts Omicron-Specific Bivalent Booster Study

The bulk of Bancel's golden parachute comes in $922.5 million in stock, based on Moderna's share price as of Dec. 31, 2021.

Moderna CEO Bancel's golden parachute soared by hundreds of millions over the pandemic

Moderna Inc. MRNA, -3.82% disclosed that Chief Executive Stéphane Bancel's 2021 salary got a 4.7% bump from the year before, while his total compensation jumped 41%, as he received the value of $3.75 million in stock awards his option awards increased 25% to $11.25 million. The increase in compensation comes as the biotechnology company grew revenue by 2,200% to $18.47 billion in 2021, due primarily to the launch of commercial sales of its COVID-19 vaccine, and as the stock soared 143%.

Moderna CEO's total compensation rose 41% in 2021, while the stock soared 143%

Shares of Moderna Inc. MRNA, +10.22% were down 1.9% in premarket trading on Thursday after the company said it began dosing patients in a Phase 2 clinical study assessing its experimental bivalent omicron-specific booster. This booster candidate has two components: an omicron-specific booster, and the COVID-19 vaccine, which is based on the original strain of the virus.

Moderna begins Phase 2 trial for bivalent COVID-19 booster for 'fall booster season'

Moderna stock has declined by almost 45% thus far in 2022 and currently trades at about $130 per share. Following the big sell-off, Moderna stock now trades at a little over 4.5x consensus 2022 earnings.

Moderna Stock Trades At Just 3x Earnings. Is It A Value Trap?

Moderna's Omicron-specific bivalent booster candidate (mRNA-1273.214) combines Moderna's Omicron-specific booster candidate (mRNA-1273.529) and the Moderna COVID-19 vaccine (mRNA-1273) Moderna expects to enroll approximately 375 participants in the U.S. CAMBRIDGE, MA / ACCESSWIRE / March 10, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant has been dosed in the Phase 2 study of the Company's Omicron-specific bivalent booster candidate (mRNA-1273.214), which combines Moderna's Omicron-specific booster candidate (mRNA-1273.529) and the Moderna COVID-19 vaccine (mRNA-1273). "We are pleased to begin this study of our bivalent booster candidate that includes our Omicron-specific candidate and the Moderna COVID-19 vaccine.

Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Bivalent Booster Candidate

CAMBRIDGE, MA / ACCESSWIRE / March 10, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host its virtual Vaccines Day for analysts and investors at 8:00 a.m. ET on Thursday, March 24.

News for Moderna Stock (MRNA)